On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

(2016) Eli M. Wallace et al.   CANCER RESEARCH

Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor

(2013) Jamie L. Rogers et al.   JOURNAL OF MEDICINAL CHEMISTRY

Allosteric inhibition of hypoxia inducible factor-2 with small molecules

(2013) Thomas H Scheuermann et al.   Nature Chemical Biology

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer

(2012) Sakari Vanharanta et al.   NATURE MEDICINE

Genetic and Functional Studies Implicate HIF1  as a 14q Kidney Cancer Suppressor Gene

(2011) C. Shen et al.   Cancer Discovery

Suppression of Hypoxia-Inducible Factor 2  Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells

(2009) A. M. Roberts et al.   CANCER RESEARCH

HIF2  inhibition promotes p53 pathway activity, tumor cell death, and radiation responses

(2009) J. A. Bertout et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Artificial ligand binding within the HIF2  PAS-B domain of the HIF2 transcription factor

(2009) T. H. Scheuermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma

(2008) John D. Gordan et al.   CANCER CELL